Here’s what the Judicial Panel on MultiDistrict Litigation has been up to with regard to Reglan/metoclopramide:
MDL No. 2049 was denied on June 3, 2009, so for the time being these cases will continue to proceed individually right where they are at. The Panel concluded that there were common factual issues about whether Reglan causes neurological injuries including tardive dyskinesia; however, the eleven filed actions had no common defendant.
Furthermore, five of the cases were in advanced stages of litigation, and to join them would have delayed resolution of those cases. All responding defendants (Actavis, Inc.; Actavis-Elizabeth, L.L.C.; Barr Pharmaceuticals, Inc.; Baxter Healthcare Corp.; Duramed Pharmaceuticals, Inc.; Pliva, Inc.; Pliva USA, Inc.; Schwarz Pharma, Inc.; Teva Pharmaceuticals USA, Inc.; and Wyeth) opposed centralization, as did one Plaintiff from Vermont.
We’re still waiting from the JPML for a ruling on Chantix, the smoking cessation drug, MDL No. 2092.